Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Fifteen-year follow up reveals cure potential in follicular lymphoma

26

Feb 2026

Fifteen-year follow up reveals cure potential in follicular lymphoma

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured.

Lymphovenous anastomosis may be an effective treatment for Alzheimer's disease

26

Feb 2026

Lymphovenous anastomosis may be an effective treatment for Alzheimer's disease

A small but growing body of evidence suggests that a minimally invasive surgical procedure called lymphovenous anastomosis (LVA) might be an effective treatment for Alzheimer's disease (AD), according to a special article in the March issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Rising vitamin K shot refusal increases newborn brain injury risk

26

Feb 2026

Rising vitamin K shot refusal increases newborn brain injury risk

Increasing numbers of parents are refusing vitamin K shots for their newborns, putting infants at greater risk of avoidable brain injuries, according to a preliminary systematic review released February 26, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.